Fifty-seven clinical isolates of enterococcus were tested for susceptibility to 10 antibiotics in a microtiter broth dilution system. Amoxicillin, ampicillin, vancomycin, and rifampin inhibited all strains at concentrations easily achievable in blood. Resistance to rifampin developed rapidly. Of the aminoglycosides, gentamicin was most active, followed in decreasing order by tobramycin, amikacin, kanamycin, and streptomycin. High-level resistance to streptomycin was present in 26% of the strains and to kanamycin in 23% of the strains. Growth curve studies of selected strains revealed synergy with ampicillin-amikacin and antagonism with ampicillin-rifampin. It is suggested that ampicillin-gentamicin constitutes adequate initial therapy for enterococcal infections until the results of tests for high-level resistance to kanamycin and streptomycin are known and that clinical trails of ampicillin-amikacin are warranted.
Most enterococci are resistant to clinically achievable blood levels of aminoglycoside antibiotics (5) . Strains resistant to streptomycin demonstrate either low-level resistance to less than 1,000 ,ug/ml or high-level 'resistance to 6,000 ,Ag/ml or more (6). Strains demonstrating high-level resistance to streptomycin are rarely synergistically affected by the addition of penicillin, whereas the majority of strains with lowlevel resistance act synergistically with penicillin (3, 6) . Similar effects have been reported for penicillin-kanamycin (9) . High-level resistance to gentamicin has not been demonstrated and penicillin and gentamicin have acted synergistically against all strains tested (6, 7, 10). Tobramycin high-level resistance has similarly not been demonstrated, and penicillin and tobramycin have been synergistic against all strains of Streptococcus faecalis tested (7) . The activity of the new aminoglycoside amikacin alone and in combination with ampicillin against enterococci has not been reported.
In the following study, the percentage of clinical enterococcal isolates showing high-level resistance to streptomycin, kanamycin, gentamicin, tobramycin, and amikacin was studied, as was the activity of ampicillin-amikacin. Finally the activities of amoxicillin, rifampin, ampicillin, cephalothin, and vancomycin were determined, and the effect of ampicillin-rifampin was investigated.
MATERIALS AND METHODS
Fifty-seven clinical isolates of enterococcus were obtained from the diagnostic microbiology laboratories of the Denver General (24 isolates), Denver Veterans Administration (18 isolates), and Colorado General (15 isolates) hospitals. Enterococci were identified as streptococci capable of growth in 6.5% NaCl and able to hydrolyze bile esculin.
A single colony from a pure culture was inoculated into 2 ml of Trypticase soy broth (TSB; Becton, Dickinson, & Co.) in a screw-cap vial and incubated at 37 C for 18 h. The vials were then frozen at -70 C until used.
Laboratory standard powders of ampicillin, amoxicillin, kanamycin, amikacin (Bristol Laboratories, Syracuse, N.Y.), tobramycin, streptomycin, cephalothin, vancomycin (Eli Lilly and Co., Indianapolis, Ind.), and gentamicin (Schering Corp., Kenilworth, N.J.) were dissolved in appropriate volumes of TSB to yield a final concentration of 200 Ag/ ml. Rifampin (Dow Chemical Corp., Indianapolis, Ind.) was dissolved in TSB with 10% dimethyl sulfoxide (Sargent Welch Corp., Denver, Col.) to a concentration of 200 ,ug/ml. Serial twofold dilutions were then made in TSB to a final concentration of 0.1 ,ig/ml. Higher concentrations of antibiotics were prepared in a similar manner. A 0.05-ml aliquot of each antibiotic concentration was placed in a microtiter well. To this was added 0.05 ml of a 10-5 dilution of an 18-h TSB culture of test organism. The trays were sealed, mixed, and incubated for 18 h at 37 C before being examined. Quantitative pourplate colony counts were performed on each inoculum to ensure that it contained 104 to 10o organisms.
The minimal inhibitory concentration (MIC) was defined as the lowest concentration of antibiotic preventing visible growth. Minimal bactericidal concentrations (MBC) were performed using a modified Steers replicator to sample 0.001 to 0.003 ml from the 0.1 ml in the microtiter plate wells, plated on Trypticase soy agar containing 5% defibrinated sheep blood, and incubated for 18 h at 37 C. The MBC was defined as the lowest concentration of antibiotic completely inhibiting bacterial growth. Staphylococcus aureus (ATCC 29923) and Escherichia coli (ATCC 29922) with known MICs and MBCs to the antibiotics tested were included as controls.
Growth curves were determined using an inoculum calculated to yield a final concentration in the test flask of 104 to 105 organisms/ml. A quantity of antibiotic calculated to result in a final concentration of 5 ,ug of ampicillin and rifampin and 12 gg of amikacin per ml was added to the test flasks. The final volume was 20 ml. The flasks were then incubated at 37 C with constant mixing, and 2-ml aliquots for quantitative culture were removed at 0, 1, 2, 4, 8, 12, and 24 h. Colony counts were carried out in duplicate and enumerated after overnight incubation at 37 C. Ampicillin and rifampin levels were determined by a modified agar-well diffusion method (1). The assay organism for ampicillin levels was S. aureus 209P, which had been rendered resistant to >100 ug of rifampin per ml by multiple passages on MuellerHinton agar to which 10 ,ug of rifampin per ml had been added. Bacillus subtilis was the assay organism for rifampin levels. To determine rifampin concentrations in the presence of ampicillin, 0.5 ml of each sample was first mixed with 0.1 ml of a betalactamase derived from Bacillus cereus 569 by the method of Sabath et al. (8) . larly showed high-level resistance to streptomycin. Two of the strains with high-level resistance to streptomycin were inhibited by 156 ,ug of kanamycin per ml. High-level resistance to gentamicin, tobramycin, and amikacin was not detected. There was no significant variation in the percentage of strains showing high-level resistance when the isolates from the three hospitals were compared. DISCUSSION Ampicillin or penicillin G, plus streptomycin or kanamycin, is currently recommended for therapy ofenterococcal infections (4). For enterococcal endocarditis, penicillin or ampicillin plus streptomycin is recommended (2). These combinations, however, are not synergistic for approximately one-quarter of the isolates from our institutions, as predicted by the presence of high-level resistance to these aminoglycosides (6, 9) . Similar observations have been reported by Moellering et al. (5) . A combination of ampicillin and gentamicin would appear to be optimal therapy for serious enterococcal infections until the results of tests for high-level resistance to streptomycin and kanamycin are available. In hospitals where these tests are not performed, therapy with ampicillin-gentamicin would appear to be indicated.
RESULTS
Although tobramycin and amikacin in combination with ampicillin are synergistic against enterococci, clinical experience with these combinations is lacking. Their place in the therapy of enterococcal infections is yet to be determined.
The activity of rifampin, at levels easily achievable in serum, might suggest that this drug would be a useful agent in the therapy of serious enterococcal infections in patients allergic to penicillin. Unfortunately, however, as with other organisms, resistance rapidly emerges. In our experience, the emergence of resistance strains was prevented by the addition of ampicillin, but the resultant combination was antagonistic. Physical incompatability and inactivation did not occur. The mechanism of this antagonism is unknown but may relate to the bacteriostatic effect of rifampin by interference with deoxyribonucleic acid-dependent ribonucleic acid polymerase, thus diminishing cell division and cell wall synthesis and precluding the bactericidal action of ampicillin at this site.
An evaluation of rifampin in combination with other antibiotics not dependent on cell wall synthesis for activity seems indicated. It is as active as vancomycin, the currently recommended drug for enterococcal infections in patients allergic to penicillin, but far less toxic.
